RDY Enterprise Value Over E B I T D A from 2010 to 2024

RDY Stock  USD 15.37  0.25  1.65%   
Dr Reddys Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Dr Reddys Enterprise Value Over EBITDA regression line of annual values had r-squared of  0.05 and arithmetic mean of  5.36. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
11.92786045
Current Value
12.52
Quarterly Volatility
3.86160702
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dr Reddys' main balance sheet or income statement drivers, such as Interest Expense of 1.8 B, Total Revenue of 293.1 B or Gross Profit of 171.8 B, as well as many indicators such as Price To Sales Ratio of 3.91, Dividend Yield of 0.0061 or PTB Ratio of 3.89. RDY financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
  
Check out the analysis of Dr Reddys Correlation against competitors.

Latest Dr Reddys' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Dr Reddys Laboratories over the last few years. It is Dr Reddys' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dr Reddys' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Pretty Stable
   Enterprise Value Over E B I T D A   
       Timeline  

RDY Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean5.36
Geometric Mean4.45
Coefficient Of Variation72.04
Mean Deviation2.91
Median3.62
Standard Deviation3.86
Sample Variance14.91
Range11.2663
R-Value0.23
Mean Square Error15.23
R-Squared0.05
Significance0.42
Slope0.20
Total Sum of Squares208.77

RDY Enterprise Value Over E B I T D A History

2024 12.52
2023 11.93
2022 2.18
2021 3.38
2020 3.62
2019 2.96
2018 4.04

About Dr Reddys Financial Statements

Dr Reddys investors use historical fundamental indicators, such as Dr Reddys' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dr Reddys. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 11.93  12.52 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.